Agilent Technologies, Inc. (BMV:A)
Mexico · Delayed Price · Currency is MXN | Market Cap | 738.89B +11.2% |
| Revenue (ttm) | 127.81B +8.6% |
| Net Income | 24.97B +18.0% |
| EPS | 87.93 +18.7% |
| Shares Out | n/a |
| PE Ratio | 29.60 |
| Forward PE | 23.33 |
| Dividend | 18.20 (0.77%) |
| Ex-Dividend Date | Jun 30, 2026 |
| Volume | 11 |
| Open | 2,350.00 |
| Previous Close | 2,350.00 |
| Day's Range | 2,350.00 - 2,350.00 |
| 52-Week Range | 1,955.54 - 2,886.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnosti... [Read more]
Financial Performance
In fiscal year 2025, Agilent Technologies's revenue was $6.95 billion, an increase of 6.73% compared to the previous year's $6.51 billion. Earnings were $1.30 billion, an increase of 1.09%.
Financial numbers in USD Financial StatementsNews
Agilent price target raised to $180 from $160 at Wells Fargo
Wells Fargo raised the firm’s price target on Agilent (A) to $180 from $160 and keeps an Overweight rating on the shares. The company’s Q3 beat and guidance raise reflects…
Agilent price target raised to $175 from $150 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Agilent (A) to $175 from $150 and keeps an Overweight rating on the shares. The firm updated the company’s model…
Agilent price target raised to $185 from $155 at RBC Capital
RBC Capital raised the firm’s price target on Agilent (A) to $185 from $155 and keeps an Outperform rating on the shares after its Q3 earnings beat and guidance raise.
Agilent price target raised to $180 from $155 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Agilent (A) to $180 from $155 and keeps a Buy rating on the shares. The firm said they posted…
Agilent price target raised to $172 from $148 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Agilent (A) to $172 from $148 and keeps an Outperform rating on the shares.
Agilent price target raised to $180 from $155 at Bernstein
Bernstein raised the firm’s price target on Agilent (A) to $180 from $155 and keeps an Outperform rating on the shares. The firm notes Agilent reported a Q3 beat and…
Agilent price target raised to $180 from $155 at Bernstein
Bernstein raised the firm’s price target on Agilent (A) to $180 from $155 and keeps an Outperform rating on the shares. The firm notes Agilent reported a Q3 beat and…
Agilent price target raised to $190 from $180 at JPMorgan
JPMorgan raised the firm’s price target on Agilent (A) to $190 from $180 and keeps an Overweight rating on the shares. The company reported a Q3 beat driven by an…
Agilent price target raised to $175 from $155 at Goldman Sachs
Goldman Sachs analyst Evie Koslosky raised the firm’s price target on Agilent (A) to $175 from $155 and keeps a Buy rating on the shares. The China recovery and advanced…
Agilent price target raised to $190 from $185 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Agilent (A) to $190 from $185 and keeps a Buy rating on the shares. The firm upped the company’s estimates…
Agilent price target raised to $180 from $170 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Agilent (A) to $180 from $170 and keeps a Buy rating on the shares. Agilent’s Q3 beat “probably won’t surprise…
Agilent price target raised to $180 from $155 at BofA
BofA analyst Michael Ryskin raised the firm’s price target on Agilent (A) to $180 from $155 and keeps a Buy rating on the shares. The set-up into FY27 continues to…
Agilent raises annual profit forecast on improving lab tools demand
Agilent Technologies raised its annual profit forecast on Wednesday, betting on improving demand for its medical tools and equipment used in lab research and drug development.
Agilent Technologies Earnings Call Transcript: Q3 2026
Q3 delivered strong revenue and EPS growth, exceeding guidance, with robust performance in pharma, advanced therapeutics, and China. FY26 guidance was raised for revenue and EPS, supported by innovation, operational execution, and strong end-market trends.
Agilent Technologies Earnings release: Q3 2026
Agilent Technologies released its Q3 2026 earnings on August 26, 2026, summarizing the period's financial results.
Agilent Technologies Slides: Q3 2026
Agilent Technologies has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 26, 2026.
Agilent up 4% at $161 after Q3 earnings beat and guidance raise
16:10 EDT Agilent (A) up 4% at $161 after Q3 earnings beat and guidance raise
Agilent reports Q3 EPS $1.62, consensus $1.49
Reports Q3 revenue $1.88B, consensus $1.84B. “Agilent’s (A) exceptional third-quarter performance reflects the sustained momentum created by our strategy, our execution discipline, and the compounding...
Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up...
Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Eastern Institute of Technology, Ningbo has received an Agilent Research Catalyst (ARC) Award on beha...
Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2026 after the stock market closes on Wednesday, Aug. 26. ...
Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received European Union (EU) certification for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagn...
Agilent Increases Its Investment in HALO X-ray Technologies
NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.
Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as ...
Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chroma...